Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amphastar PharmaceuticalsAMPH -1.72%84 Days Sales Outstanding is 72.62 as of Jun. 2026, which is 25% above its 10-year median of 57.90. GuruFocus rates AMPH with a GF Score™ of 84/100 and a GF Value™ of $35.99 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 946 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 50.42% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals Days Sales Outstanding Chart
AMPH vs PCRX, COLL, IRWD: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Days Sales Outstanding falls into.
Amphastar Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a Days Sales Outstanding of 72.62 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Amphastar Pharmaceuticals and its competitors. This is 25% above median its historical median of 57.90. Over the past decade, Amphastar Pharmaceuticals' Days Sales Outstanding has ranged from 42.92 to 71.60. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #469 out of 946 companies in the Drug Manufacturers industry, placing it in the top 49.6%.
Is Amphastar Pharmaceuticals' Days Sales Outstanding too high?
Amphastar Pharmaceuticals' current Days Sales Outstanding of 72.62 is 25% above median its 10-year median of 57.90. Over the past 10 years, this metric has ranged from a low of 42.92 to a high of 71.60. The Drug Manufacturers industry median Days Sales Outstanding is 71.89. Amphastar Pharmaceuticals' value of 72.62 is 1% above this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #469 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Days Sales Outstanding compare to PCRX and COLL?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #469 out of 946 companies for Days Sales Outstanding. This puts Amphastar Pharmaceuticals in the upper half of its industry. The industry median Days Sales Outstanding is 71.89. Amphastar Pharmaceuticals' value of 72.62 is 1% above this benchmark. Historically, Amphastar Pharmaceuticals' own Days Sales Outstanding has ranged from 42.92 to 71.60 over the past decade. While the company's 10-year median is 57.90 vs. the industry median of 71.89, Amphastar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.89, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current Days Sales Outstanding of 72.62 is 1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current Days Sales Outstanding is 72.62, which is 25% above median its own 10-year median of 57.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.99, compared to a current price of $23.43 — trading 34.9% below its estimated fair value. The current Days Sales Outstanding is 72.62, which is 25% above median its 10-year median of 57.90 and 1% above the Drug Manufacturers industry median of 71.89. Amphastar Pharmaceuticals' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Days Sales Outstanding is 72.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $23.43 is trading 34.9% below its estimated GF Value™ of $35.99.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Days Sales Outstanding: 72.62 (25% above median its 10-year median of 57.90)
GF Value™: $35.99 vs. price of $23.43 (34.9% below fair value)
Industry Position: 1% above the Drug Manufacturers median (#469 of 946)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
84GF Score
Get the complete analysis for AMPH
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
